Vaccination recommendations for patients with neuromuscular disease

Susanna Esposito, Claudio Bruno, Angela Berardinelli, Massimiliano Filosto, Tiziana Mongini, Lucia Morandi, Olimpia Musumeci, Elena Pegoraro, Gabriele Siciliano, Paola Tonin, Gianni Marrosu, Carlo Minetti, Maura Servida, Chiara Fiorillo, Giorgio Conforti, Silvia Scapolan, Filippo Ansaldi, Andrea Vianello, Silvana Castaldi, Nicola PrincipiAntonio Toscano, Maurizio Moggio

Research output: Contribution to journalArticle

Abstract

Neuromuscular diseases (NMDs) encompass a broad spectrum of conditions. Because infections may be relevant to the final prognosis of most NMDs, vaccination appears to be the simplest and most effective solution for protecting NMD patients from vaccine-preventable infections. However, very few studies have evaluated the immunogenicity, safety, tolerability, and efficacy of different vaccines in NMD patients; therefore, detailed vaccination recommendations for NMD patients are not available. Here, we present vaccination recommendations from a group of Italian Scientific Societies for optimal disease prevention in NMD patients that maintain high safety levels. We found that NMD patients can be classified into two groups according to immune function: patients with normal immunity and patients who are immunocompromised, including those who intermittently or continuously take immunosuppressive therapy. Patients with normal immunity and do not take immunosuppressive therapy can be vaccinated as healthy subjects. In contrast, immunocompromised patients, including those who take immunosuppressive therapy, should receive all inactivated vaccines as well as influenza and pneumococcal vaccines; these patients should not be administered live attenuated vaccines. In all cases, the efficacy and long-term persistence of immunity from vaccination in NMD patients can be lower than in normal subjects. Household contacts of immunocompromised NMD patients should also be vaccinated appropriately.

Original languageEnglish
Pages (from-to)5893-5900
Number of pages8
JournalVaccine
Volume32
Issue number45
DOIs
Publication statusPublished - Oct 14 2014

Fingerprint

neuromuscular disorders
Neuromuscular Diseases
Vaccination
vaccination
immunosuppressive agents
Immunosuppressive Agents
Immunity
Immunocompromised Host
immunity
live vaccines
vaccines
Vaccines
therapeutics
Safety
Pneumococcal Vaccines
Attenuated Vaccines
Inactivated Vaccines
Influenza Vaccines
Infection
inactivated vaccines

Keywords

  • Chronic disease
  • Immunocompromised patients
  • Influenza vaccination
  • Neurologic disease
  • Neuromuscular disease
  • Pneumococcal vaccine

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine
  • Medicine(all)

Cite this

Esposito, S., Bruno, C., Berardinelli, A., Filosto, M., Mongini, T., Morandi, L., ... Moggio, M. (2014). Vaccination recommendations for patients with neuromuscular disease. Vaccine, 32(45), 5893-5900. https://doi.org/10.1016/j.vaccine.2014.09.003

Vaccination recommendations for patients with neuromuscular disease. / Esposito, Susanna; Bruno, Claudio; Berardinelli, Angela; Filosto, Massimiliano; Mongini, Tiziana; Morandi, Lucia; Musumeci, Olimpia; Pegoraro, Elena; Siciliano, Gabriele; Tonin, Paola; Marrosu, Gianni; Minetti, Carlo; Servida, Maura; Fiorillo, Chiara; Conforti, Giorgio; Scapolan, Silvia; Ansaldi, Filippo; Vianello, Andrea; Castaldi, Silvana; Principi, Nicola; Toscano, Antonio; Moggio, Maurizio.

In: Vaccine, Vol. 32, No. 45, 14.10.2014, p. 5893-5900.

Research output: Contribution to journalArticle

Esposito, S, Bruno, C, Berardinelli, A, Filosto, M, Mongini, T, Morandi, L, Musumeci, O, Pegoraro, E, Siciliano, G, Tonin, P, Marrosu, G, Minetti, C, Servida, M, Fiorillo, C, Conforti, G, Scapolan, S, Ansaldi, F, Vianello, A, Castaldi, S, Principi, N, Toscano, A & Moggio, M 2014, 'Vaccination recommendations for patients with neuromuscular disease', Vaccine, vol. 32, no. 45, pp. 5893-5900. https://doi.org/10.1016/j.vaccine.2014.09.003
Esposito, Susanna ; Bruno, Claudio ; Berardinelli, Angela ; Filosto, Massimiliano ; Mongini, Tiziana ; Morandi, Lucia ; Musumeci, Olimpia ; Pegoraro, Elena ; Siciliano, Gabriele ; Tonin, Paola ; Marrosu, Gianni ; Minetti, Carlo ; Servida, Maura ; Fiorillo, Chiara ; Conforti, Giorgio ; Scapolan, Silvia ; Ansaldi, Filippo ; Vianello, Andrea ; Castaldi, Silvana ; Principi, Nicola ; Toscano, Antonio ; Moggio, Maurizio. / Vaccination recommendations for patients with neuromuscular disease. In: Vaccine. 2014 ; Vol. 32, No. 45. pp. 5893-5900.
@article{5a9c1157cbb4454dbde71af0a93d7b5a,
title = "Vaccination recommendations for patients with neuromuscular disease",
abstract = "Neuromuscular diseases (NMDs) encompass a broad spectrum of conditions. Because infections may be relevant to the final prognosis of most NMDs, vaccination appears to be the simplest and most effective solution for protecting NMD patients from vaccine-preventable infections. However, very few studies have evaluated the immunogenicity, safety, tolerability, and efficacy of different vaccines in NMD patients; therefore, detailed vaccination recommendations for NMD patients are not available. Here, we present vaccination recommendations from a group of Italian Scientific Societies for optimal disease prevention in NMD patients that maintain high safety levels. We found that NMD patients can be classified into two groups according to immune function: patients with normal immunity and patients who are immunocompromised, including those who intermittently or continuously take immunosuppressive therapy. Patients with normal immunity and do not take immunosuppressive therapy can be vaccinated as healthy subjects. In contrast, immunocompromised patients, including those who take immunosuppressive therapy, should receive all inactivated vaccines as well as influenza and pneumococcal vaccines; these patients should not be administered live attenuated vaccines. In all cases, the efficacy and long-term persistence of immunity from vaccination in NMD patients can be lower than in normal subjects. Household contacts of immunocompromised NMD patients should also be vaccinated appropriately.",
keywords = "Chronic disease, Immunocompromised patients, Influenza vaccination, Neurologic disease, Neuromuscular disease, Pneumococcal vaccine",
author = "Susanna Esposito and Claudio Bruno and Angela Berardinelli and Massimiliano Filosto and Tiziana Mongini and Lucia Morandi and Olimpia Musumeci and Elena Pegoraro and Gabriele Siciliano and Paola Tonin and Gianni Marrosu and Carlo Minetti and Maura Servida and Chiara Fiorillo and Giorgio Conforti and Silvia Scapolan and Filippo Ansaldi and Andrea Vianello and Silvana Castaldi and Nicola Principi and Antonio Toscano and Maurizio Moggio",
year = "2014",
month = "10",
day = "14",
doi = "10.1016/j.vaccine.2014.09.003",
language = "English",
volume = "32",
pages = "5893--5900",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "45",

}

TY - JOUR

T1 - Vaccination recommendations for patients with neuromuscular disease

AU - Esposito, Susanna

AU - Bruno, Claudio

AU - Berardinelli, Angela

AU - Filosto, Massimiliano

AU - Mongini, Tiziana

AU - Morandi, Lucia

AU - Musumeci, Olimpia

AU - Pegoraro, Elena

AU - Siciliano, Gabriele

AU - Tonin, Paola

AU - Marrosu, Gianni

AU - Minetti, Carlo

AU - Servida, Maura

AU - Fiorillo, Chiara

AU - Conforti, Giorgio

AU - Scapolan, Silvia

AU - Ansaldi, Filippo

AU - Vianello, Andrea

AU - Castaldi, Silvana

AU - Principi, Nicola

AU - Toscano, Antonio

AU - Moggio, Maurizio

PY - 2014/10/14

Y1 - 2014/10/14

N2 - Neuromuscular diseases (NMDs) encompass a broad spectrum of conditions. Because infections may be relevant to the final prognosis of most NMDs, vaccination appears to be the simplest and most effective solution for protecting NMD patients from vaccine-preventable infections. However, very few studies have evaluated the immunogenicity, safety, tolerability, and efficacy of different vaccines in NMD patients; therefore, detailed vaccination recommendations for NMD patients are not available. Here, we present vaccination recommendations from a group of Italian Scientific Societies for optimal disease prevention in NMD patients that maintain high safety levels. We found that NMD patients can be classified into two groups according to immune function: patients with normal immunity and patients who are immunocompromised, including those who intermittently or continuously take immunosuppressive therapy. Patients with normal immunity and do not take immunosuppressive therapy can be vaccinated as healthy subjects. In contrast, immunocompromised patients, including those who take immunosuppressive therapy, should receive all inactivated vaccines as well as influenza and pneumococcal vaccines; these patients should not be administered live attenuated vaccines. In all cases, the efficacy and long-term persistence of immunity from vaccination in NMD patients can be lower than in normal subjects. Household contacts of immunocompromised NMD patients should also be vaccinated appropriately.

AB - Neuromuscular diseases (NMDs) encompass a broad spectrum of conditions. Because infections may be relevant to the final prognosis of most NMDs, vaccination appears to be the simplest and most effective solution for protecting NMD patients from vaccine-preventable infections. However, very few studies have evaluated the immunogenicity, safety, tolerability, and efficacy of different vaccines in NMD patients; therefore, detailed vaccination recommendations for NMD patients are not available. Here, we present vaccination recommendations from a group of Italian Scientific Societies for optimal disease prevention in NMD patients that maintain high safety levels. We found that NMD patients can be classified into two groups according to immune function: patients with normal immunity and patients who are immunocompromised, including those who intermittently or continuously take immunosuppressive therapy. Patients with normal immunity and do not take immunosuppressive therapy can be vaccinated as healthy subjects. In contrast, immunocompromised patients, including those who take immunosuppressive therapy, should receive all inactivated vaccines as well as influenza and pneumococcal vaccines; these patients should not be administered live attenuated vaccines. In all cases, the efficacy and long-term persistence of immunity from vaccination in NMD patients can be lower than in normal subjects. Household contacts of immunocompromised NMD patients should also be vaccinated appropriately.

KW - Chronic disease

KW - Immunocompromised patients

KW - Influenza vaccination

KW - Neurologic disease

KW - Neuromuscular disease

KW - Pneumococcal vaccine

UR - http://www.scopus.com/inward/record.url?scp=84907997133&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907997133&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2014.09.003

DO - 10.1016/j.vaccine.2014.09.003

M3 - Article

C2 - 25223270

AN - SCOPUS:84907997133

VL - 32

SP - 5893

EP - 5900

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 45

ER -